vs
ADMA BIOLOGICS, INC.（ADMA）与DOMO, INC.（DOMO）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是DOMO, INC.的1.8倍（$139.2M vs $79.4M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs -13.1%，领先48.6%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -0.5%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $1.1M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -0.5%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Domo股份有限公司是总部设在美国犹他州美国福克的美国云软件企业，主营人工智能、商业智能与数据可视化业务，属于SaaS（软件即服务）企业，核心产品可帮助企业各层级决策者在极少IT介入的情况下，实时获取业务数据，支撑决策开展。
ADMA vs DOMO — 直观对比
营收规模更大
ADMA
是对方的1.8倍
$79.4M
营收增速更快
ADMA
高出18.8%
-0.5%
净利率更高
ADMA
高出48.6%
-13.1%
自由现金流更多
ADMA
多$33.5M
$1.1M
两年增速更快
ADMA
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $79.4M |
| 净利润 | $49.4M | $-10.4M |
| 毛利率 | 63.8% | 74.2% |
| 营业利润率 | 45.1% | -8.7% |
| 净利率 | 35.5% | -13.1% |
| 营收同比 | 18.4% | -0.5% |
| 净利润同比 | -55.9% | 44.6% |
| 每股收益（稀释后） | $0.20 | $-0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMADOMO
| Q4 25 | $139.2M | $79.4M | ||
| Q3 25 | $134.2M | $79.7M | ||
| Q2 25 | $122.0M | $80.1M | ||
| Q1 25 | $114.8M | $78.8M | ||
| Q4 24 | $117.5M | $79.8M | ||
| Q3 24 | $119.8M | $78.4M | ||
| Q2 24 | $107.2M | $80.1M | ||
| Q1 24 | $81.9M | $80.2M |
净利润ADMADOMO
| Q4 25 | $49.4M | $-10.4M | ||
| Q3 25 | $36.4M | $-22.9M | ||
| Q2 25 | $34.2M | $-18.1M | ||
| Q1 25 | $26.9M | $-17.7M | ||
| Q4 24 | $111.9M | $-18.8M | ||
| Q3 24 | $35.9M | $-19.5M | ||
| Q2 24 | $32.1M | $-26.0M | ||
| Q1 24 | $17.8M | $-18.7M |
毛利率ADMADOMO
| Q4 25 | 63.8% | 74.2% | ||
| Q3 25 | 56.3% | 74.8% | ||
| Q2 25 | 55.1% | 74.2% | ||
| Q1 25 | 53.2% | 74.4% | ||
| Q4 24 | 53.9% | 75.0% | ||
| Q3 24 | 49.8% | 74.3% | ||
| Q2 24 | 53.6% | 74.1% | ||
| Q1 24 | 47.8% | 76.3% |
营业利润率ADMADOMO
| Q4 25 | 45.1% | -8.7% | ||
| Q3 25 | 38.0% | -9.1% | ||
| Q2 25 | 35.1% | -17.9% | ||
| Q1 25 | 30.4% | -15.6% | ||
| Q4 24 | 32.6% | -13.9% | ||
| Q3 24 | 33.1% | -18.5% | ||
| Q2 24 | 36.6% | -26.8% | ||
| Q1 24 | 26.7% | -16.6% |
净利率ADMADOMO
| Q4 25 | 35.5% | -13.1% | ||
| Q3 25 | 27.1% | -28.8% | ||
| Q2 25 | 28.1% | -22.5% | ||
| Q1 25 | 23.4% | -22.4% | ||
| Q4 24 | 95.2% | -23.5% | ||
| Q3 24 | 30.0% | -24.9% | ||
| Q2 24 | 29.9% | -32.5% | ||
| Q1 24 | 21.7% | -23.3% |
每股收益（稀释后）ADMADOMO
| Q4 25 | $0.20 | $-0.25 | ||
| Q3 25 | $0.15 | $-0.56 | ||
| Q2 25 | $0.14 | $-0.45 | ||
| Q1 25 | $0.11 | $-0.45 | ||
| Q4 24 | $0.45 | $-0.48 | ||
| Q3 24 | $0.15 | $-0.51 | ||
| Q2 24 | $0.13 | $-0.69 | ||
| Q1 24 | $0.08 | $-0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | — |
| 总债务越低越好 | $72.1M | $124.2M |
| 股东权益账面价值 | $477.3M | $-191.9M |
| 总资产 | $624.2M | $201.6M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMADOMO
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | $47.2M | ||
| Q1 25 | $71.6M | $45.3M | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | $61.2M | ||
| Q1 24 | $45.3M | $60.9M |
总债务ADMADOMO
| Q4 25 | $72.1M | $124.2M | ||
| Q3 25 | $72.4M | $121.9M | ||
| Q2 25 | — | $119.7M | ||
| Q1 25 | — | $117.7M | ||
| Q4 24 | $72.3M | $115.6M | ||
| Q3 24 | — | $115.2M | ||
| Q2 24 | — | $114.1M | ||
| Q1 24 | — | $113.5M |
股东权益ADMADOMO
| Q4 25 | $477.3M | $-191.9M | ||
| Q3 25 | $431.2M | $-191.5M | ||
| Q2 25 | $398.3M | $-178.7M | ||
| Q1 25 | $373.4M | $-177.2M | ||
| Q4 24 | $349.0M | $-171.2M | ||
| Q3 24 | $231.9M | $-166.4M | ||
| Q2 24 | $188.3M | $-163.5M | ||
| Q1 24 | $153.7M | $-153.5M |
总资产ADMADOMO
| Q4 25 | $624.2M | $201.6M | ||
| Q3 25 | $568.7M | $195.7M | ||
| Q2 25 | $558.4M | $189.7M | ||
| Q1 25 | $510.6M | $214.3M | ||
| Q4 24 | $488.7M | $190.2M | ||
| Q3 24 | $390.6M | $197.8M | ||
| Q2 24 | $376.4M | $204.4M | ||
| Q1 24 | $350.9M | $225.7M |
负债/权益比ADMADOMO
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $3.4M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $1.1M |
| 自由现金流率自由现金流/营收 | 24.8% | 1.4% |
| 资本支出强度资本支出/营收 | 0.8% | 2.9% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $9.9M |
8季度趋势，按日历期对齐
经营现金流ADMADOMO
| Q4 25 | $35.6M | $3.4M | ||
| Q3 25 | $13.3M | $3.4M | ||
| Q2 25 | $21.1M | $4.0M | ||
| Q1 25 | $-19.7M | $8.9M | ||
| Q4 24 | $50.2M | $-13.7M | ||
| Q3 24 | $25.0M | $-6.2M | ||
| Q2 24 | $45.6M | $1.9M | ||
| Q1 24 | $-2.2M | $5.4M |
自由现金流ADMADOMO
| Q4 25 | $34.6M | $1.1M | ||
| Q3 25 | $-1.1M | $1.0M | ||
| Q2 25 | $18.7M | $1.0M | ||
| Q1 25 | $-24.4M | $6.7M | ||
| Q4 24 | $47.5M | $-16.2M | ||
| Q3 24 | $24.0M | $-8.4M | ||
| Q2 24 | $43.6M | $-625.0K | ||
| Q1 24 | $-4.6M | $2.9M |
自由现金流率ADMADOMO
| Q4 25 | 24.8% | 1.4% | ||
| Q3 25 | -0.8% | 1.3% | ||
| Q2 25 | 15.3% | 1.3% | ||
| Q1 25 | -21.2% | 8.5% | ||
| Q4 24 | 40.4% | -20.3% | ||
| Q3 24 | 20.0% | -10.7% | ||
| Q2 24 | 40.7% | -0.8% | ||
| Q1 24 | -5.6% | 3.6% |
资本支出强度ADMADOMO
| Q4 25 | 0.8% | 2.9% | ||
| Q3 25 | 10.7% | 2.9% | ||
| Q2 25 | 2.0% | 3.7% | ||
| Q1 25 | 4.1% | 2.8% | ||
| Q4 24 | 2.3% | 3.2% | ||
| Q3 24 | 0.9% | 2.8% | ||
| Q2 24 | 1.9% | 3.2% | ||
| Q1 24 | 2.9% | 3.1% |
现金转化率ADMADOMO
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
DOMO
| Subscription | $71.9M | 91% |
| Professional Servicesand Other | $7.5M | 9% |
